Disease severity for enrollment criteria of patients with idiopathic pulmonary fibrosis (IPF) in clinical trial: evaluation of time to first episode of acute exacerbation (TTA)

S. Ohkouchi, T. Abe, Y. Taguchi, M. Ebina, T. Nukiwa (Sendai, Tenri, Japan)

Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Session: A wide spectrum of idiopathic pulmonary fibrosis
Session type: Thematic Poster Session
Number: 667
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Ohkouchi, T. Abe, Y. Taguchi, M. Ebina, T. Nukiwa (Sendai, Tenri, Japan). Disease severity for enrollment criteria of patients with idiopathic pulmonary fibrosis (IPF) in clinical trial: evaluation of time to first episode of acute exacerbation (TTA). Eur Respir J 2009; 34: Suppl. 53, 667

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Clinical application of the COPD assessment test (CAT) in patients with idiopathic pulmonary fibrosis
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017

Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features
Source: Eur Respir J 2006; 27: 143-150
Year: 2006



Prevalence of heart disease in patients hospitalized for an acute exacerbation of COPD: Impact on clinical outcome. A 6 month follow-up study
Source: Annual Congress 2011 - COPD management
Year: 2011

Late-breaking abstract: Pathological analysis of acute exacerbation of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases
Year: 2011

Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015


A randomised controlled trial of individualised, progressed early exercise in patients hospitalised with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
Source: International Congress 2015 – Latest insights in pulmonary rehabilitation and functional capacity
Year: 2015


Chronic obstructive pulmonary disease assessment test (CAT) in patients with COPD, chronic heart failure (CHF), and both
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016

Comparison of patient-reported outcomes (PROs) during acute exacerbation of chronic obstructive pulmonary disease
Source: International Congress 2016 – Monitoring airway diseases with clinical tools
Year: 2016


Persistence of clinical criteria of chronic bronchitis in patients with COPD over time: A longitudinal analysis of the TRACE cohort.
Source: International Congress 2017 – Markers of COPD progression
Year: 2017


Patient’s knowledge about risk factors for acute exacerbation( AE ) of chronic obstructive pulmonary disease( COPD )
Source: Eur Respir J 2004; 24: Suppl. 48, 514s
Year: 2004

Regional differences in the treatment of patients with moderate COPD enrolled in a global clinical trial
Source: Annual Congress 2006 - Recent advances in the treatment of COPD
Year: 2006


Evaluation of adequacy of pharmacological treatment in relation to severity in patients with chronic obstructive pulmonary disease (COPD) and their clinical correlations.
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018

All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013

Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015



Clinical characteristics, pulmonary function, and response to beta2-agonist: Patients with asthma vs. patients with asthma/COPD overlap syndrome
Source: Annual Congress 2013 –Asthma at the bedside
Year: 2013


Chronic obstructive pulmonary disease (COPD) patients with bronchiectasis: clinical features?
Source: International Congress 2018 – COPD exacerbations and bronchiectasis
Year: 2018


A clinical and outcomes assessment of the management of acute episodes of chronic bronchitis (AECB) : the MOSAIC study - baseline characteristics of screened patients
Source: Eur Respir J 2002; 20: Suppl. 38, 544s
Year: 2002

Short term glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: "REDUCE*", a non-inferiority multicenter trial. (*Reduction in the Use of Corticosteroids in Exacerbated COPD; ISRCTN19646069)
Source: Annual Congress 2012 - Acute exacerbation in COPD
Year: 2012

Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012


The availibility of copd assessment test (CAT) in determination of risk of early hospitalization in chronic obstructive pulmonary disease patients and its correlation with pulmonary function tests, dyspnea measurement scales and St George respiratory questionnaire
Source: International Congress 2014 – COPD markers
Year: 2014